Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 22, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - November 22, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/22/17 - "Crystalline Form of a Substituted Quinoline Compound and Pharmaceutical Compositions Thereof" in Patent Application Approval Process (USPTO...
"Crystalline Form of a Substituted Quinoline Compound and Pharmaceutical Compositions Thereof" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Xi, Ning; Sun, Mingming, filed on November 12, 2016, was made available online on November 9, 2017, according to news repo
11/22/17 - "Treatment of Erectile Dysfunction and Other Indications" in Patent Application Approval Process (USPTO 20170312288)
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventor Fossel, Eric T., filed on July 18, 2017, was made available online on November 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Strategic Science& Technologies LLC. Curre
11/22/17 - A New Official Store Selling PhenQ Released!
Phenq is one of the effective dietary supplements that aim to ensure appetite suppression and weight loss. While going through the different Phenq reviews 2017, one is likely to find more of positive reviews for losing weight faster and more easily than before. Keeping the rave reviews in mind, has come up with an official store and
11/22/17 - Acorda axes Parkinsons drug after trial deaths [All Iraq News Agency (AIN)]
Acorda Therapeutics has abandoned development of its Parkinsons drug, tozadenant, just days after putting trials on hold following a series of patient deaths. Based in New York state, Acorda said it made the decision after finding new information from phase 3 studies, related to the previously disclosed safety issues with agranulocytosis a lack of
11/22/17 - Allergic Reaction: Allergens Cause Dangerous Spike in FDA Recalled Food Units in Q3
By a News Reporter-Staff News Editor at Immunotherapy Weekly Recalled FDA food units increased 19 percent to 106.6 million in the third quarter of 2017- higher than 20 of the last 22 quarters- and public health risks rose sharply due to a spike in undeclared food allergens found in food products, according to the Q3 2017 Recall Index from Stericy
11/22/17 - Amazon more interested in shipping medical devices for now [Tehran Times (Iran)]
Coupled with its purchase of grocery chain Whole Foods, the suggestion was that the firm could distribute prescription drugs via these newly purchased outlets. Despite not suggesting any concrete plans, Olsavskys comments spooked shareholders in both Walgreens and CVS two of the US biggest pharmacy chains leading to an almost 6% share price drop fo
11/22/17 - ARRAY BIOPHARMA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Array Biopharma, Inc. To Contact The Firm [African Manager (Tunisia)]
-Faruqi& Faruqi, LLP, a leading national securities law firm, reminds investors in Array Biopharma, Inc. of the January 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Array Biopharma stock or options between December 16, 2015 and March 17, 2017 an
11/22/17 - As Prescription Drug Prices Soar, Financial Education Benefits Center Will Offer an Rx Discount Benefit
Prescription drug prices are higher in the United States than almost anywhere else in the world. "Prescriptions are necessary for so many people to not only live a healthy life but just to simply live," said Jennifer Martinez, manager at FEBC. Because the United States has no national healthcare system like the U.K. or Canada, there's no way to
11/22/17 - Banner Life Sciences Assigned Patent for Fumarate Ester Pharmaceutical Compositions
Banner Life Sciences, High Point, North Carolina, has been assigned a patent developed by three co-inventors for "fumarate ester pharmaceutical compositions." The co-inventors are Tatyana Dyakonov, Greensboro, North Carolina, Sunil Agnihotri, Scarborough, Maine, and Aqeel A. Fatmi, High Point, North Carolina. Written by Kusum Sangma; edited by Suda
11/22/17 - Biologics Safety Testing Market Is Estimated to Represent US $4.36 Bn During 2017-2022: Testing the safety of these biologics is critical for avoiding the inadvertent inclusion of unknown entities in drug manufacturing system.
A recently published report by Persistence Market Research projects that the global market for biologics safety testing will soar at a robust CAGR of 8.8% over the forecast period, 2017-2022. The report anticipates that approx. According to the report, North America will remain at the forefront of global expansion of biologics safety testing market
11/22/17 - Biopharma firms are all the rage on the Kosdaq [Arab Finance (Egypt)]
On Monday, Samsung Bioepis announced that it received final approval for the sale of its anti-cancer drug Ontruzant in Europe. The two biggest markets were the United States and Europe. Samsung Bioepis had already succeeded in getting approval to sell three biosimilar drugs in Europe.
11/22/17 - CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023 - Research and Markets
The "CD Antigen Cancer Therapy Market Outlook& Clinical Trials Insight 2023" report has been added to Research and Markets' offering. CD Antigen Cancer Therapy Market Outlook& Clinical Trials Insight 2023 report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cance
11/22/17 - Clinical Laboratory Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Global Clinical Laboratory Services Market: Scope and Methodology. This report on the global clinical laboratory services market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.Read the f
11/22/17 - Debiopharm International SA Launches Clinical Trials Website:
LAUSANNE, Switzerland, November 22, 2017/ PRNewswire/. The website provides patients and their caregivers with helpful information on Debiopharm's clinical trials and studies. Debiopharm's main therapeutic areas are oncology and infectious diseases.
11/22/17 - Federal Register Table of Contents
Table of Contents Office of the Federal Register Agriculture Department NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals, 55553 Bureau of Consumer Financial Protection RULES Arbitration Agreements, 55500 Centers for Disease Control and Prevention NOTICES Agency Information Collection Activities; Proposals,...
11/22/17 - Future Scope of Allergic Rhinitis market | World Major Key Players survey with 2023 Forecast
Market Research Future has a half cooked research report on global allergic rhinitis market. This market is growing at an average rate and is expected to show similar trends till 2023.. Hay fever is another name for allergic rhinitis which is a nose related disease.
11/22/17 - General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products; Guidance for Industry; Availability
SUMMARY: The Food and Drug Administration is announcing the availability of a guidance for industry entitled "General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products." The guidance recommends studies, including comparative in vitro and pharmacokinetic studies, that a potential ANDA applicant should conduct
11/22/17 - Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
By a News Reporter-Staff News Editor at Biotech Week Ionis Pharmaceuticals, Inc. and Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5Rx, a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy, for which Ionis earned a $5 million license fee in the form of Dynacure equity. We are pleased that Dy
11/22/17 - Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection
Janssen Therapeutics, Division of Janssen Products, LP, today announced that the U.S. Food and Drug Administration has approved JULUCA (R), the first, complete, single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 infection in certain adults living with the disease who are virologically suppressed. JULUCA (R) is a
11/22/17 - Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX (Daratumumab) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Johnson and Johnson issued the following news release:. Janssen Biotech, Inc. today announced that it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for DARZALEX (R). As part of the application, Janssen has requested Priority Review, which the FDA grants to investigational therapies that, if appr
11/22/17 - Juluca (Dolutegravir and Rilpivirine) Approved in US as First 2-drug Regimen, Once-daily, Single Pill - a Complete Regimen for the Maintenance Treatment of Virologically Suppressed HIV-1 Infection
Deborah Waterhouse, CEO ViiV Healthcare said, "The FDA approval of Juluca marks an important milestone in our commitment to deliver innovative advances in HIV care by providing new treatment options that challenge the traditional approach to care. This FDA approval is based primarily upon data from two pivotal phase III clinical trials, SWORD-1 and
11/22/17 - Juluca (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration has approved Juluca , indicated as a complete regimen for the maintenance treatment of HIV-1 infection in adults who are virologically suppressed o
11/22/17 - Khondrion Presents Phase II KHENERGY Trial Data
Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY study, a Phase II exploratory trial with oral KH176 in the m.3243A> G multisystem mitochondrial MELAS and MIDD syndromes and mixed phenotypes. Jan Smeitink, Khondrion's CEO, at the
11/22/17 - Ligand Reports Third Quarter 2017 Financial Results
By a News Reporter-Staff News Editor at Biotech Week Ligand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2017, and provided an operating forecast and program updates. We announced positive results for a major phase 2 trial for our diabetes drug candidate and are in discussions with part
11/22/17 - Millions Suffer as Opioids Curtailed
Six months after surgery to repair a damaged urinary tract in 1998, computer technician Doug Hale woke one morning with excruciating, burning pain. Hale s suffering persisted for years, despite all sorts of treatments. Still on his pain killers, Hale, of Rutland, was popping so many of the highly addictive pills that he regularly ran out of his
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement